Following on from information provided to NICE by the company in November 2015, the appraisal of Leukaemia (acute lymphoblastic, Philadelphia negative) - vincristine liposomal (after 2 therapies) [ID954] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.